- Home
- HYI vs PRQR Comparison
HYI vs PRQR Comparison
Compare HYI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYI
- PRQR
- Stock Information
- Founded
- HYI 2010
- PRQR 2012
- Country
- HYI United States
- PRQR Netherlands
- Employees
- HYI N/A
- PRQR N/A
- Industry
- HYI Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- HYI Finance
- PRQR Health Care
- Exchange
- HYI Nasdaq
- PRQR Nasdaq
- Market Cap
- HYI 279.2M
- PRQR 309.5M
- IPO Year
- HYI N/A
- PRQR 2014
- Fundamental
- Price
- HYI $12.14
- PRQR $3.61
- Analyst Decision
- HYI
- PRQR Strong Buy
- Analyst Count
- HYI 0
- PRQR 4
- Target Price
- HYI N/A
- PRQR $7.13
- AVG Volume (30 Days)
- HYI 50.6K
- PRQR 668.4K
- Earning Date
- HYI 01-01-0001
- PRQR 11-07-2024
- Dividend Yield
- HYI 9.59%
- PRQR N/A
- EPS Growth
- HYI N/A
- PRQR N/A
- EPS
- HYI N/A
- PRQR N/A
- Revenue
- HYI N/A
- PRQR $20,506,357.00
- Revenue This Year
- HYI N/A
- PRQR $298.83
- Revenue Next Year
- HYI N/A
- PRQR N/A
- P/E Ratio
- HYI N/A
- PRQR N/A
- Revenue Growth
- HYI N/A
- PRQR 306.68
- 52 Week Low
- HYI $10.99
- PRQR $1.18
- 52 Week High
- HYI $12.24
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- HYI 49.92
- PRQR 54.32
- Support Level
- HYI $11.94
- PRQR $3.57
- Resistance Level
- HYI $12.22
- PRQR $4.21
- Average True Range (ATR)
- HYI 0.14
- PRQR 0.24
- MACD
- HYI -0.00
- PRQR -0.08
- Stochastic Oscillator
- HYI 52.63
- PRQR 20.00
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. It invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.